ResultsIQ

ResultsIQ › Latest results › Zydus Lifesciences Limited

Zydus Lifesciences Limited Q3 FY26 results deck summary

NSE: ZYDUSLIFE · BSE: 532321

Results deck of 9 Feb 2026, summarised by AI from the filing.

Total revenues ₹68,645 mn in Q3 FY26, up 30.3% YoY from ₹52,691 mn.

Key takeaways

  1. Revenue Total revenues ₹68,645 mn in Q3 FY26, up 30.3% YoY from ₹52,691 mn.
  2. Risk Exchange rate fluctuations on operating transactions were a loss of ₹1,649 mn in Q3 FY26.

Original filing on BSE

Zydus Lifesciences Limited Q1 FY27 results

As filed: Revenue ₹8,017 cr (+22% year on year), EBITDA ₹1,929 cr (−8% year on year), PAT ₹990 cr (−35% year on year), EBITDA margin 24.1% (−771 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹7,587 cr (+16% year on year), EBITDA ₹2,554 cr (+20% year on year), PAT ₹1,341 cr (+9% year on year), EBITDA margin 33.7% (+110 bps). Score 37 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit before exceptional items growth was well below it. EBITDA margin rose 110 bps year on year. Consolidated profit +8% but standalone -39%. Revenue rose ₹1,059 cr on a year ago, more than the ₹994 cr it added the year before. Share price after the results: +8.4% in 30 days (Nifty 500: +3.3%).
  • Q3 FY26: Revenue ₹6,865 cr (+30% year on year), EBITDA ₹1,816 cr (+31% year on year), PAT ₹1,023 cr (0% year on year), EBITDA margin 26.5% (+14 bps). Score 63 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit growth was below it. EBITDA margin rose 14 bps year on year. Profit fell 17% from last quarter. Share price after the results: +3.8% in 30 days (Nifty 500: −5.9%).
  • Q2 FY26: Revenue ₹6,123 cr (+17% year on year), EBITDA ₹2,015 cr (+38% year on year), PAT ₹1,239 cr (+35% year on year), EBITDA margin 32.9% (+499 bps). Score 76 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA growth was well above it; profit growth was in line with it. EBITDA margin rose 499 bps year on year. Revenue fell 7% from last quarter. Profit rose ₹319 cr on a year ago, more than the ₹117 cr it added the year before. Share price after the results: −4.1% in 29 days (Nifty 500: +0.7%).
  • Q1 FY26: Revenue ₹6,574 cr (+6% year on year), EBITDA ₹2,089 cr (0% year on year), PAT ₹1,521 cr (+3% year on year), EBITDA margin 31.8% (−179 bps). Score 15 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin fell 179 bps year on year. Consolidated profit +3% but standalone -77%. Revenue rose ₹366 cr on a year ago, against ₹1,068 cr the year before. Share price after the results: +9.2% in 30 days (Nifty 500: +2.1%).
  • Q4 FY25: Revenue ₹6,528 cr (+18% year on year), EBITDA ₹2,126 cr (+30% year on year), PAT ₹1,244 cr (+22% year on year), EBITDA margin 32.6% (+310 bps). Score 62 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit before exceptional items growth was below it. EBITDA margin rose 310 bps year on year. Consolidated profit 0% but standalone +100%. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue rose ₹994 cr on a year ago, more than the ₹523 cr it added the year before. Share price after the results: +4.3% in 30 days (Nifty 500: −0.4%).
  • Q3 FY25: Revenue ₹5,269 cr (+17% year on year), EBITDA ₹1,387 cr (+26% year on year), PAT ₹1,026 cr (+30% year on year), EBITDA margin 26.3% (+184 bps). Score 65 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was below it. EBITDA margin rose 184 bps year on year. Profit rose ₹236 cr on a year ago, more than the ₹159 cr it added the year before.
  • Q2 FY25: Revenue ₹5,237 cr (+20% year on year), EBITDA ₹1,462 cr (+28% year on year), PAT ₹920 cr (+15% year on year), EBITDA margin 27.9% (+169 bps). Score 68 of 100, Above trend. EBITDA margin rose 169 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 16% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Zydus Lifesciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.